{
    "clinical_study": {
        "@rank": "53723", 
        "arm_group": [
            {
                "arm_group_label": "Tarceva (Erlotinib)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "gemcitabine/cisplatin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is an extension to ENSURE, a study of Tarceva (erlotinib) versus\n      gemcitabine/cisplatin combination chemotherapy (GP) as the first-line treatment for patients\n      with non-small cell lung cancer (NSCLC) with mutations in the tyrosine kinase domain of\n      EGFR.\n\n      This study is designed to examine the efficacy of Tarceva versus GP as a second-line\n      treatment in NSCLC patients from the ENSURE trial. Patients previously treated with GP will\n      be given Tarceva (150 mg orally) daily until disease progression or unacceptable toxicity\n      occurs. Patients previously treated with Tarceva will be given cisplatin (75 mg/m2\n      intravenously [IV]) on Day 1 and gemcitabine (1250 mg/m2 IV) on Days 1 and 8 of 3-week\n      chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles\n      (whichever comes first)."
        }, 
        "brief_title": "A Study of Second-Line Therapy With Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participant in ENSURE trial\n\n          -  Disease progression during first-line treatment\n\n        Exclusion Criteria:\n\n          -  N/A"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000531", 
            "org_study_id": "ML29028"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tarceva (Erlotinib)", 
                "description": "150 mg oral dose given once daily. Given as second-line treatment at investigator's discretion after disease progression in ENSURE trial.", 
                "intervention_name": "Erlotinib [Tarceva]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "gemcitabine/cisplatin", 
                "description": "A 1250 mg/m2 intravenous infusion on Days 1 and 8 of each 3-week cycle, until disease progression, unacceptable toxicity or up to 4 cycles, whichever comes first. Given as second-line treatment at investigator's discretion after disease progression in ENSURE trial.", 
                "intervention_name": "gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "gemcitabine/cisplatin", 
                "description": "A 75 mg/m2 intravenous infusion on Day 1 of each 3-week cycle, until disease progression, unacceptable toxicity or up to 4 cycles, whichever comes first. Given as second-line treatment at investigator's discretion after disease progression in ENSURE trial.", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "101149"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "zip": "130012"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510080"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "zip": "210002"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200030"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200030"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200433"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shantou", 
                        "country": "China", 
                        "zip": "515041"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "ENSURE Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva) and Erlotinib After Disease Progression in Chinese Population Enrolled in the ENSURE Trial", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML29028 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "People&apos;s Republic of China: CFDA"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival (PFS), defined as time from randomization until either disease progression on second-line treatment or death from any cause after disease progression on first-line treatment.", 
            "safety_issue": "No", 
            "time_frame": "Approximately 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000531"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Approximately 6 months"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}